These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33489083)

  • 1. Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice.
    Dashtipour K; Gupta F; Hauser RA; Karunapuzha CA; Morgan JC
    Parkinsons Dis; 2021; 2021():2603641. PubMed ID: 33489083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
    Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
    Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions.
    Isaacson SH; Citrome L
    Expert Opin Drug Saf; 2022 Jul; 21(7):873-879. PubMed ID: 35466847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis.
    Isaacson SH; Pahwa R; Pagan F; Abler V; Truong D
    Clin Park Relat Disord; 2024; 10():100256. PubMed ID: 38770047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.
    Torres-Yaghi Y; Carwin A; Carolan J; Nakano S; Amjad F; Pagan F
    Neuropsychiatr Dis Treat; 2021; 17():3791-3818. PubMed ID: 34992373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.
    Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S
    Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis.
    Yunusa I; Rashid N; Seyedin R; Paratane D; Rajagopalan K
    J Geriatr Psychiatry Neurol; 2023 Sep; 36(5):417-432. PubMed ID: 36720473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
    Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H
    Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments.
    Rojas M; Chávez-Castillo M; Duran P; Ortega Á; Bautista-Sandoval MJ; Salazar J; Riaño-Garzón M; Chacín M; Medina-Ortiz O; Palmar J; Cudris-Torres L; Bermúdez V
    Curr Pharm Des; 2022; 28(33):2725-2741. PubMed ID: 36321314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Pimavanserin and Maintenance Electroconvulsive Therapy: A Novel Approach to Parkinson's Disease Psychosis.
    Imlay RK; Alsayed M; Starcher M; Tager A; Griffith J
    Cureus; 2024 Jul; 16(7):e64316. PubMed ID: 39130906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden.
    Fredericks D; Norton JC; Atchison C; Schoenhaus R; Pill MW
    Am J Manag Care; 2017 Apr; 23(5 Suppl):S83-S92. PubMed ID: 28715903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurological commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
    Hermanowicz N
    CNS Spectr; 2018 Dec; 23(6):352-354. PubMed ID: 30588904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
    Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
    Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
    Kianirad Y; Simuni T
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease psychosis: presentation, diagnosis and management.
    Schneider RB; Iourinets J; Richard IH
    Neurodegener Dis Manag; 2017 Dec; 7(6):365-376. PubMed ID: 29160144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine.
    Abdul-Rahman T; Herrera-Calderón RE; Aderinto N; Kundu M; Wireko AA; Adebusoye FT; Ekerin O; Lawal L; Mykolaivna NI; Alexiou A; Almashjary MN; Perveen A; Ashraf GM
    J Integr Neurosci; 2024 Apr; 23(4):80. PubMed ID: 38682215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.
    Pagan FL; Schulz PE; Torres-Yaghi Y; Pontone GM
    CNS Drugs; 2024 May; 38(5):333-347. PubMed ID: 38587586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychosis in Parkinson's Disease: Current Treatment Options and Impact on Patients and Caregivers.
    Segal GS; Xie SJ; Paracha SU; Grossberg GT
    J Geriatr Psychiatry Neurol; 2021 Jul; 34(4):274-279. PubMed ID: 34219522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pimavanserin in the Treatment of Parkinson's Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials.
    Mansuri Z; Reddy A; Vadukapuram R; Trivedi C; Amara A
    Innov Clin Neurosci; 2022; 19(1-3):46-51. PubMed ID: 35382074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label study.
    Evidente VGH; DeKarske D; Coate B; Abler V
    Ther Adv Neurol Disord; 2024; 17():17562864241228350. PubMed ID: 38476466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.